Literature DB >> 22772606

DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis.

André O von Bueren1, Joachim Gerss, Christian Hagel, Haoyang Cai, Marc Remke, Martin Hasselblatt, Burt G Feuerstein, Sarah Pernet, Olivier Delattre, Andrey Korshunov, Stefan Rutkowski, Stefan M Pfister, Michael Baudis.   

Abstract

Little is known about frequency, association with clinical characteristics, and prognostic impact of DNA copy number alterations (CNA) on survival in central primitive neuroectodermal tumors (CNS-PNET) and tumors of the pineal region. Searches of MEDLINE, Pubmed, and EMBASE--after the original description of comparative genomic hybridization in 1992 and July 2010--identified 15 case series of patients with CNS-PNET and tumors of the pineal region whose tumors were investigated for genome-wide CNA. One additional case study was identified from contact with experts. Individual patient data were extracted from publications or obtained from investigators, and CNAs were converted to a digitized format suitable for data mining and subgroup identification. Summary profiles for genomic imbalances were generated from case-specific data. Overall survival (OS) was estimated using the Kaplan-Meier method, and by univariable and multivariable Cox regression models. In their overall CNA profiles, low grade tumors of the pineal region clearly diverged from CNS-PNET and pineoblastoma. At a median follow-up of 89 months, 7-year OS rates of CNS-PNET, pineoblastoma, and low grade tumors of the pineal region were 22.9 ± 6, 0 ± 0, and 87.5 ± 12 %, respectively. Multivariable analysis revealed that histology (CNS-PNET), age (≤2.5 years), and possibly recurrent CNAs were associated with unfavorable OS. DNA copy number profiling suggests a close relationship between CNS-PNET and pineoblastoma. Low grade tumors of the pineal region differed from CNS-PNET and pineoblastoma. Due to their high biological and clinical variability, a coordinated prospective validation in future studies is necessary to establish robust risk factors.

Entities:  

Mesh:

Year:  2012        PMID: 22772606     DOI: 10.1007/s11060-012-0911-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  44 in total

1.  Adult medulloblastoma comprises three major molecular variants.

Authors:  Marc Remke; Thomas Hielscher; Paul A Northcott; Hendrik Witt; Marina Ryzhova; Andrea Wittmann; Axel Benner; Andreas von Deimling; Wolfram Scheurlen; Arie Perry; Sidney Croul; Andreas E Kulozik; Peter Lichter; Michael D Taylor; Stefan M Pfister; Andrey Korshunov
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study.

Authors:  Barry L Pizer; Claire L Weston; Kathryn J Robinson; David W Ellison; James Ironside; Frank Saran; Linda S Lashford; Diana Tait; Helen Lucraft; David A Walker; Clifford C Bailey; Roger E Taylor
Journal:  Eur J Cancer       Date:  2006-04-24       Impact factor: 9.162

3.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

4.  Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas.

Authors:  Stefan Pfister; Marc Remke; Grischa Toedt; Wiebke Werft; Axel Benner; Frank Mendrzyk; Andrea Wittmann; Frauke Devens; Katja von Hoff; Stefan Rutkowski; Andreas Kulozik; Bernhard Radlwimmer; Wolfram Scheurlen; Peter Lichter; Andrey Korshunov
Journal:  Genes Chromosomes Cancer       Date:  2007-09       Impact factor: 5.006

5.  Systematic reviews using individual patient data: a map for the minefields?

Authors:  M Clarke; J Godwin
Journal:  Ann Oncol       Date:  1998-08       Impact factor: 32.976

6.  Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances.

Authors:  S Solinas-Toldo; S Lampel; S Stilgenbauer; J Nickolenko; A Benner; H Döhner; T Cremer; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1997-12       Impact factor: 5.006

7.  Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials.

Authors:  Beate Timmermann; Rolf-Dieter Kortmann; Joachim Kühl; Stefan Rutkowski; Christof Meisner; Torsten Pietsch; Frank Deinlein; Christian Urban; Monika Warmuth-Metz; Michael Bamberg
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

8.  Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors.

Authors:  C Russo; M Pellarin; O Tingby; A W Bollen; K R Lamborn; G Mohapatra; V P Collins; B G Feuerstein
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

9.  Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization.

Authors:  S Joos; U S Bergerheim; Y Pan; H Matsuyama; M Bentz; S du Manoir; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1995-12       Impact factor: 5.006

10.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

View more
  6 in total

1.  New gene signatures for pediatric brain tumors: a step forward in the understanding of molecular basis of CNS PNET.

Authors:  Raúl Alelú-Paz; Santiago Ropero
Journal:  Transl Pediatr       Date:  2013-01

2.  Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.

Authors:  Elke Pfaff; Christian Aichmüller; Martin Sill; Damian Stichel; Matija Snuderl; Matthias A Karajannis; Martin U Schuhmann; Jens Schittenhelm; Martin Hasselblatt; Christian Thomas; Andrey Korshunov; Marina Rhizova; Andrea Wittmann; Anna Kaufhold; Murat Iskar; Petra Ketteler; Dietmar Lohmann; Brent A Orr; David W Ellison; Katja von Hoff; Martin Mynarek; Stefan Rutkowski; Felix Sahm; Andreas von Deimling; Peter Lichter; Marcel Kool; Marc Zapatka; Stefan M Pfister; David T W Jones
Journal:  Acta Neuropathol       Date:  2019-11-25       Impact factor: 17.088

3.  Common molecularcytogenetic alterations in tumors originating from the pineal region.

Authors:  Florian Böhrnsen; Christina Enders; Hans-Christoph Ludwig; Wolfgang Brück; Laszlo Füzesi; Angelika Gutenberg
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

4.  MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system .

Authors:  Marco Gessi; André O von Bueren; Andras Treszl; Anja zur Mühlen; Wolfgang Hartmann; Monika Warmuth-Metz; Stefan Rutkowski; Torsten Pietsch
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

5.  Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.

Authors:  David R Raleigh; David A Solomon; Shane A Lloyd; Ann Lazar; Michael A Garcia; Penny K Sneed; Jennifer L Clarke; Michael W McDermott; Mitchel S Berger; Tarik Tihan; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

Review 6.  Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors.

Authors:  Jenny Adamski; Vijay Ramaswamy; Annie Huang; Eric Bouffet
Journal:  F1000Prime Rep       Date:  2014-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.